PERINATAL MENTAL HEALTH GUIDELINES ON DEPRESSION & ANXIETY

FEBRUARY 2023

ACADEMY OF MEDICINE SINGAPORE

COLLEGE OF OBSTETRICIANS & GYNAECOLOGISTS, SINGAPORE
INTRODUCTION

The lifetime prevalence of major depression and generalized anxiety disorder has been found to be 7.7-9.2% and 1.9-2.2% amongst women of childbearing age (Subramaniam et al 2020, Singapore Mental Health Study), whilst antepartum depressive states (both major and minor) occur in 12.2% and postpartum depressive states in 6.8% (Chee et al 2006). The neurodevelopmental impact of depression and anxiety on the growing fetus has been clearly evidenced in the Singapore population (GUSTO birth cohort study), with changes in microstructure, functional connectivity as well as epigenetic footprint. The adverse impact extends into the postpartum period, during which maternal depression and anxiety have been found to be associated with infant negative temperament, reduced maternal sensitivity, child behavioural problems, and decreased school readiness (www.gusto.sg). Given that preconception mental health has been found to be closely related to antenatal mental health, which in turn predicts postnatal mental health, there is a crucial need for early identification and intervention to ensure the best health outcomes for women and children. These guidelines have been developed to provide guidance on addressing depression and anxiety, during the preconception, antepartum and postpartum phases.

AIM OF GUIDELINE

Target audience: GPs, Fam Med/ PHPs, OGYN, Paeds, Nursing, mental health professionals

We aim to make this document readable to the wider public and non-healthcare lay community, as awareness and public education is a key factor to addressing maternal mental health at the population level.

This guideline does not include the severe mental disorders such as schizophrenic and bipolar disorders, which will be covered in subsequent editions.
1. ADDRESSING PRECONCEPTION DEPRESSION AND ANXIETY

1.1 Advice on pregnancy planning

i) Consider pregnancy prevention or contraception for women and girls of childbearing potential with a past or current depressive or anxiety disorder as they are particularly vulnerable to the stress of an unplanned pregnancy.

ii) Consider any previous history of depression or anxiety, as this is a well-established risk factor for antenatal depression or anxiety (Biaggi 2016).

iii) Plan well for pregnancy, as pregnancy unintendedness is a risk factor associated with perinatal depression (Abajobir et al, 2016)

1.2 Preconception counselling on impact of maternal mental illness and treatment

i) Provide information to women of childbearing potential with a severe depressive or anxiety disorder regarding how their mental health condition and its treatment might affect them or their baby if they become pregnant (McCloskey et al, 2020).

ii) Tailor this information according to their individual needs, and illness pattern.

iii) With information, women can make an informed decision about family planning, and make necessary arrangements to prepare for pregnancy. (McCloskey et al, 2020)

1.3 Lifestyle adjustments to optimize preconception mental health

i) Provide guidance to women of childbearing potential with pre-existing depressive or anxiety disorder to help them make lifestyle adjustments to optimize their mental wellbeing and general health (van Lee et al, 2022).

ii) Recommendations include improving nutrition with whole foods diet, weight management, smoking cessation, alcohol abstinence and folate supplementation to promote maternal mental wellbeing, and fetal development. Physical activity, exercise and mindfulness practice can also help reduce symptoms of depression or anxiety and promote wellbeing. (Dennis et al, 2022)

1.4 Medication use in consideration of childbearing

i) Consider carefully safe choices of psychotropic medication or mood stabilizer, particularly valproate, for women or girls of childbearing potential who might require long-term treatment for their mood disorder (UK Nice guidelines).

ii) Restrict the use of valproate to when there are no effective or tolerated alternatives, and when pregnancy prevention plan is adequate, as valproate is teratogenic. (Shakespeare & Sisodiya 2020)
1.5 Holistic approach to preconception mental health

i) Consider psychological therapies, and address social stressors, to optimize the control of pre-existing depressive or anxiety disorder, as this can help to minimize the dose of antidepressant medication needed; any cessation should be discussed in preconception care planning.

ii) Aim to achieve minimum effective dose of psychotropic medication to maintain wellness during conception. Maternal mental health state tends to remain stable from preconception to pregnancy (Kee et al 2021).

iii) Addressing any conflicts can ameliorate the risk of depression perinatally as couple relationship strength is particularly important - (Westdhal et al 2012).
2. ADDRESSING ANTENATAL DEPRESSION AND ANXIETY

2.1. Screening for antenatal depression/anxiety

i) Early screening for antenatal depression during obstetric visits provides an ideal opportunity for preventative care and treatment before delivery (Marcus et al, 2003).

ii) A short screen such as the Patient Health Questionnaire PHQ-2 may be used:

   “Over the last 2 weeks, how often have you been bothered by:
   ➢ Little interest or pleasure in doing things?
   ➢ Feeling down, depressed or hopeless?”

Women who experience either/both symptoms for most days, can be considered screen-positive, and will benefit from support or referral for further assessment. (see Appendix 1 for full version of PHQ-2)

iii) Women may also be screened using a validated questionnaire such as the Edinburgh Postnatal Depression Scale EPDS (Appendix 2), with follow-up actions according to clear referral and management protocols.

iv) Consider that antenatal depression is more common than postnatal depression (Chee et al, 2005), and that antenatal depression and anxiety are significant risk factors for postnatal depression (M.N., Norhayati, W.M.A., Wan Emilin, 2015)

v) Consider using Generalized Anxiety Disorder 2-item (GAD-2) with further assessment to follow, but take note that there is currently no robust evidence for a reliable screening tool for antenatal anxiety. (Appendix 3)

2.2. Assessment of antenatal depression/anxiety

i) Clinical diagnoses should be made based on criteria listed in DSM-5 or ICD-10.

ii) Consider holistic aspects of care such as: other psychiatric co-morbidities (such as learning disability, alcohol and substance use disorders), medical and obstetric health, quality of partner and other familial relationships, care of older children, financial and occupational stressors, lifestyle practices, bonding with unborn child

iii) Consider assessing for risk of harm to self and others (including fetus). (NICE, 2015)

2.3. Medication use in antenatal depression/ anxiety

i) Antidepressants are recommended for women with moderate to severe illness, or at risk of clinically significant relapse, with careful consideration of potential benefits and risks of antenatal use of antidepressants (Yonkers et al, 2009)

ii) Factors to consider include: symptom severity, risk of relapse/worsening, impact of illness vs. medication on mother and fetus, patient’s response to previous treatment, stage of pregnancy, patient preference (Yonkers et al, 2009)
iii) Clinicians should provide information regarding the risk of septal defects with selective serotonin reuptake inhibitors, particularly Paroxetine, and discuss risk-benefit considerations. (Molenaar et al. 2018)

iv) Good practices for prescribing safely include: lowest effective doses, divided over the day if necessary, avoiding first-trimester use if possible, frequent and regular reviews. (NICE, 2014)

2.4. Holistic approach to care for patients with antenatal depression/anxiety

i) Care for women should be coordinated amongst relevant healthcare professionals, which may include general and family medicine practitioners, obstetricians and gynecologists, pediatricians, psychiatrists, nurses, counsellors, social workers and midwives (Donker et al. 2009).

ii) Having relevant mental health information enables women (and their partners/family, with their agreement) to make informed, collaborative decisions about their care.

iii) Information should include potential benefits and side effects of treatment, consequences of untreated illness, which may include poor maternal health, lower quality of life, difficulties with social relationships, poor mother-infant bonding, and poor overall development of the infant. (Sioman et al. 2019)

iv) Lifestyle behavioural interventions targeting diet, sleep, physical activity, smoking and having social support helps to prevent and reduce antenatal depressive symptoms (van Lee et al, 2020)

v) Non-pharmacological interventions, such as supportive therapy, psychology therapy and group therapy, may be beneficial, in addition to pharmacological interventions. (Bowen et. al, 2014)

2.5. Monitoring and supporting women receiving care for antenatal depression/anxiety

i) Regular monitoring of symptoms and response to treatment during the antenatal period is recommended (NICE, 2014).

ii) Consider referral to perinatal psychiatric services at KKH, NUH, IMH for women with severe depression or anxiety, or those not responding to treatment.

iii) Having adequate social and emotional support from husbands/partners (Dunkel S.C., 2011) and family in the antenatal period can help reduce depressive and anxiety symptoms (Spoozak et al, 2009).
3. ADDRESSING POSTNATAL DEPRESSION AND ANXIETY

3.1. Screening for postnatal depression and anxiety:

i) Early screening for postnatal depression during obstetric visits provide an ideal opportunity for preventative care and treatment. (ACOG Committee Opinion, 2018; Chen 2011). Well child visits to the paediatrician or primary health practitioner are also an opportune time to screen the mother for postnatal depression (Earl 2010).

ii) Screening is particularly important for women with risk factors of postnatal depression and anxiety, which include antenatal depression/ anxiety, recent stressful life events and inadequate social support (Beck 2001)

iii) A short screen such as the Patient Health Questionnaire PHQ-2 may be used:

“Over the last 2 weeks, how often have you been bothered by:
Little interest or pleasure in doing things?
 Feeling down, depressed or hopeless?”

Women who experience either/both symptoms for most days, can be considered screen-positive, and will benefit from support or referral for further assessment. (see Appendix 1 for full version of PHQ-2)

iv) Women may also be screened using a validated questionnaire such as the Edinburgh Postnatal Depression Scale EPDS (Appendix 2), with follow-up actions according to clear referral and management protocols.

v) Consider using Generalized Anxiety Disorder 2-item (GAD-2) with further assessment to follow, but take note that there is currently no robust evidence for a reliable screening tool for postnatal anxiety. (Appendix 3)

3.2. Assessment of postnatal depression and anxiety:

i) Clinical diagnoses should be made based on criteria listed in DSM-5 or ICD-10

ii) Consider holistic aspects of care such as: other psychiatric co-morbidities (such as learning disability, alcohol and substance use disorders), medical and obstetric health, quality of partner and other familial relationships, care of older children, financial and occupational stressors, lifestyle practices, bonding with baby.

iii) Consider assessing for risk of harm to self and others (including baby).

3.3. Medication use in postnatal depression/ anxiety

i) Provide counselling on the risk and benefits of starting pharmacological treatment, including potential consequences of untreated depression/ anxiety and adverse side effects of antidepressants. (Brown et al. 2021)
ii) Provide support for women in their decision about breastfeeding and be aware that antidepressant use is not an absolute contraindication to breastfeeding. (Brown et al. 2021)

3.4. Holistic approach to care for patients with postnatal depression/anxiety

i) Care for women should be coordinated amongst relevant healthcare professionals, which may include general and family medicine practitioners, obstetricians and gynecologists, pediatricians, psychiatrists, nurses, counsellors, social workers and midwives.

ii) Having relevant mental health information enables women (and their partners/family, with their agreement) to make informed, collaborative decisions about their care (Donker et al. 2009)

iii) Information should include potential benefits and side effects of treatment, consequences of untreated illness, which may include poor maternal health, lower quality of life, difficulties with social relationships, poor mother-infant bonding, and poor overall development of the infant. (Slomian et al. 2019)

iv) Lifestyle advice such as those related to healthy eating, physical activity and sleep hygiene could be provided to women, in consideration of the adjustment of these activities during the postnatal period. (COPE 2018)

v) Supportive counselling or structured individual psychological intervention, such as cognitive behavioural therapy or interpersonal psychotherapy, may improve depressive symptoms. (NICE 2015, COPE 2017)

vi) Consider interventions to improve mother-baby bonding if there are concerns with their relationship as women with depressive symptoms may experience challenges with bonding. (NICE 2015)

3.5. Monitoring and supporting women receiving care for postnatal depression/anxiety

i) Regular monitoring of symptoms and response to treatment during the postnatal period is recommended.

ii) Consider referral to perinatal psychiatric services at KKH, NUH, IMH for women with severe depression or anxiety, or those not responding to treatment.

iii) Having adequate social and emotional support from husbands/partners and family in the postnatal period can help reduce depressive and anxiety symptoms. (Machado et al. 2020)
SPECIAL CONSIDERATIONS

Women who have experienced a severe maternal event - such as hemorrhage requiring massive transfusion and/or hysterectomy, severe hypertensive crises, eclamptic seizures, sepsis, thrombotic events and cardiovascular failure, stillbirth or intrauterine death – are particularly at risk of depression and anxiety, as well as post-traumatic stress disorder. (Furuta et al, BMC Pregnancy and Childbirth 2014) Care and support should be provided for the patient, as well as the healthcare providers, who might experience emotional effects of severe adverse events (Morton et al, JOGNN 2021).

Women with special needs will benefit from care delivery that is tailored to address their needs (D’Angelo et al, 2020). Likewise, pregnant adolescents can be at higher risk of perinatal depression (Siegel & Brandon, 2014). Additional effort to provide information and support for these vulnerable mothers can mitigate the development of depression and anxiety in their perinatal experience.

Infant neurodevelopment is related to the quality of caregiving. Maternal mental health can influence maternal attunement and sensitivity to infant needs (Rifkin-Gabro et al, 2015), and maternal mind-mindedness(Bigelow et al, 2018). Mothers are encouraged to spend quality time attending to and caring for their infants, by following baby’s cues and keeping mindful of baby’s needs. Research shows that mothers staying present, watching and wondering about their infants can improve maternal reflective capacity (Bakermans-kranenburg et al, 2003). Red flags for dysfunction in mother-infant dyads include reduced maternal attunement, reduced child responsiveness to mother and restricted growth and development (Tsang et al, 2019).
   Level III evidence (cross-sectional population survey)

   Level III evidence (cross-sectional study)

   Level II evidence (systematic review)

   Level II evidence (systematic review; not involving RCTs)

   Level II evidence (systematic review)

6. Dennis CL, Brown HK, Brennenstuhl S, Vigod S, Miller A, Castro RA. Preconception risk factors and health care needs of pregnancy-planning women and men with a lifetime history or current mental illness: a nationwide survey. PLOS One 2022 17(6); e0270158; doi:10.1371/journal.pone.0279158
   Level II evidence (cross-sectional survey)

7. Shakespeare J, Sisodiya SM. Royal College of General Practitioners Guidance document on valproate use in women and girls of childbearing years. 2020 Dec Version 2
   Level IV evidence (expert opinion)

8. UK National Institute of Health and Care Excellence Guidelines on Antenatal and postnatal mental health: clinical management and service guideline. Published December 2014, updated Feb 2020; 1.2.2 Considerations for women with childbearing potential; www.nice.org.uk/guidance/cg192
   Level IV evidence (expert opinion)

   Level II evidence (cohort study)

   **Level II evidence (cohort study)**


   **Level II (Evidence cohort study)**


   **Level IV (Expert opinion)**


   **Level IV (Expert opinion)**


   **Level IV (Expert opinion)**


   **Level IV (Expert opinion)**


   **Level IV (Expert opinion)**


   **Level IV (Expert opinion)**


   **Level IV (Expert opinion)**


   **Level IV (Expert opinion)**

**Level IV (Cross-sectional study)**


**Level IV (Systematic review of descriptive studies)**


**Level III (Cross-sectional study)**


**Level I (Systematic review of RCT)**


**Level II (Systematic review of descriptive studies)**


**Level IV (Narrative review)**


**Level II (Case control study)**


**Level IV (Expert opinion)**


**Level IV (Expert opinion)**


**Level II (Meta-analysis of descriptive studies)**

**Level II (Systematic review of descriptive studies)**


**Level I (Systematic review of RCT)**


**Level II (Systematic review of descriptive studies)**


**Level II (Systematic review of descriptive studies)**


**Level II (Cohort study)**


**Level IV (Expert Opinion)**


**Level IV (Expert Opinion)**


**Level II (Review)**


**Level II (Cohort study)**


**Level II (Cohort study)**

   Level I (Metaanalyses)


   Level III (Case report)
## Correspondence and Chief of Panel

| (1) A/Prof Helen Chen Yu  
MBBS, MMed (Psychiatry), Grad Dip Psychotherapy (dynamic) | Senior Consultant Psychiatrist & Head  
Department of Psychological Medicine  
Women's and Children's Hospital  
Duke-National University of Singapore |
|---|---|

## Co-Authors

| (2) Dr Chua Tze-Ern  
MBBS, MMed (Psychiatry) | Senior Consultant Psychiatrist & Head  
Women's Mental Wellness Service  
Department of Psychological Medicine  
KK Women's and Children's Hospital  
Duke-National University of Singapore |
|---|---|
| (3) Dr Theresa Lee  
MBBS, MMed (Psychiatry), Grad Dip Psychotherapy (dynamic) | Senior Consultant  
Women's Mental Wellness Service  
Department of Psychological Medicine  
KK Women's and Children's Hospital  
Duke-National University of Singapore |
| (4) Dr Elizabeth Siak Junpei  
MBBS, MRCPsych (UK) | Consultant  
Women’s Mental Wellness Service  
Department of Psychological Medicine  
KK Women's and Children's Hospital  
Duke-National University of Singapore |
| (5) Dr Hong Lin Feng  
MBBS (Australia), MRCPsych (UK), | Senior Consultant  
Women’s Mental Wellness Service  
Department of Psychological Medicine  
KK Women's and Children's Hospital  
Duke-National University of Singapore |
| (6) Ms Ch’ng Ying Chia  
MA Applied Social Studies  
Grad Dip Counselling Practice  
Post Grad Dip Family Therapy & Systemic Practice | Principal Clinical Counsellor  
Women’s Mental Wellness Service  
Department of Psychological Medicine  
KK Women's and Children's Hospital  
Singapore |
| (7) Ms Yasmin Hassan  
BA (Social Work with honours)  
Grad Dip Counselling Practice | Senior Clinical Counsellor  
Women’s Mental Wellness Service  
Department of Psychological Medicine  
KK Women's and Children's Hospital  
Singapore |
| (8) Dr Cornelia Chee Yin Ing  
MBBS, MMed (Psychiatry) | Senior Consultant & Head  
Department of Psychological Medicine  
National University Hospital  
Yong Loo Lin School of Medicine, NUS |
| (9) Dr Mok Yee Ming  
MB BCh BAO (Dublin),  
MMed (Psychiatry), Grad Dip (Psychotherapy) | Senior Consultant, Chief (Mood & Anxiety)  
Assistant Chairman Medical Board (Clinical)  
Institute of Mental Health |
| (10) | A/Prof Ong Say How  
| MBBS, MMed (Psychiatry)  
| Grad Dip Psychotherapy, FAMS | Senior Consultant, Chief  
| Department of Developmental Psychiatry  
| Institute of Mental Health |
| (11) | Prof Victor Samuel Rajadurai  
| MBBS, MD(Paed),  
| MRCP(UK Paed) | Emeritus Consultant  
| Department of Neonatology  
| KK Women’s and Children’s Hospital |
| (12) | Dr Teoh Tiong Ghee  
| MD, MSc, MRCP(I), FRCOG | Director, Maternal and Child Global Health and Care Transformation  
| Senior Consultant  
| Obstetrics & Gynaecology  
| KK Women’s and Children’s Hospital |
| (13) | Ms Vasuki Utravarthy  
| B Social Science with honours(NUS),  
| MHealth Admin, MPublic Health(NUS) | Director  
| Outreach School Health & Outreach Division  
| Health Promotion Board |
| (14) | Prof Tan Kok Hian  
| MBBS, MMed (O&G), FRCOG, MBA | Senior Consultant & Head  
| Perinatal Audit & Epidemiology  
| Obstetrics & Gynaecology  
| KK Women’s and Children’s Hospital  
| Duke-National University of Singapore |
| (15) | A/Prof Tan Lay Kok  
| MBBS, MMed (O&G), FRCOG | Senior Consultant, Head  
| Department of Maternal Fetal Medicine  
| Obstetrics & Gynaecology  
| KK Women’s and Children’s Hospital |
**APPENDIX 1**

**PATIENT HEALTH QUESTIONNAIRE 2-item (PHQ-2)**

*(Kroenke K, Spitzer RL, Williams JOB. The Patient Health Questionnaire-2: Validity of a Two-item Depression Screener. Medical Care, 2003:41:1284-92)*

Over the last 2 weeks, how often have you been bothered by the following problems?

1. Little interest or pleasure in doing thing
   - Not at all 0
   - Several days 1
   - More than half the days 2
   - Nearly every day 3

2. Feeling down, depressed or hopeless
   - Not at all 0
   - Several days 1
   - More than half the days 2
   - Nearly every day 3

**Interpretation:**
- The authors have identified a score of 3 to be the optimal cut-off when using PHQ-2 to screen for major depression (or clinical depression).
- Patients who screen positive should be further evaluated and attended to accordingly.
## EDINBURGH POSTNATAL DEPRESSION SCALE (EPDS)


1. I have been able to laugh and see the funny side of things in the past one week.
   - 0: As much as I always could
   - 1: Not quite so much now
   - 2: Definitely not so much now
   - 3: Not at all

2. I have looked forward with enjoyment to things in the past one week.
   - 0: As much as I ever did
   - 1: Rather less than I used to
   - 2: Definitely less than I used to
   - 3: Hardly at all

3. I have blamed myself unnecessarily when things went wrong in the past one week.
   - 0: No, never
   - 1: Not very often
   - 2: Yes, some of the time
   - 3: Yes, most of the time

4. I have been anxious or worried for no good reason in the past one week.
   - 0: No, not at all
   - 1: Hardly ever
   - 2: Yes, sometimes
   - 3: Yes, very often

5. I have felt scared or panicky for no very good reason in the past one week.
   - 0: No, not at all
   - 1: No, not much
   - 2: Yes, sometimes
   - 3: Yes, quite a lot

6. Things have been getting on top of me in the past one week.
   - 0: No, I have been coping as well as ever
   - 1: No, most of the time I have coped quite well
   - 2: Yes, sometimes I haven’t been coping as well as usual
   - 3: Yes, most of the time I haven’t been able to cope at all

7. I have been so unhappy that I have had difficulty sleeping in the past one week.
   - 0: No, not at all
   - 1: Not very often
   - 2: Yes, sometimes
   - 3: Yes, most of the time

8. I have felt sad or miserable in the past one week.
   - 0: No, not at all
   - 1: Not very often
   - 2: Yes, quite often
   - 3: Yes, most of the time

9. I have thought of harming myself has occurred to me in the past one week.
   - 0: No, never
   - 1: Only occasionally
   - 2: Yes, quite often
   - 3: Yes, most of the time

10. I have felt sad or miserable in the past one week.
Screening is considered positive if one or more of the following is met:
- Total score 15 or more for antenatal depression
- Total score 13 or more for postnatal depression
- Item score of 1 or more on item 10

**GENERALIZED ANXIETY DISORDER 2-item (GAD-2)**


The brief General Anxiety Disorder 2-item (GAD-2) may be used to screen for symptoms of anxiety:

1. Over the last 2 weeks, how often have you been bothered by feeling nervous, anxious or on edge?
   - Not at all: 0
   - Several days: 1
   - More than half the days: 2
   - Nearly every day: 3

2. Over the last 2 weeks, how often have you been bothered by not being able to stop or control worrying?
   - Not at all: 0
   - Several days: 1
   - More than half the days: 2
   - Nearly every day: 3

**Interpretation:**
A score of 3 or more has been suggested to be suggestive of generalized anxiety, and further assessment is warranted.

*Please note that GAD-2 has not be validated in Singapore, and its psychometric properties as a screening tool for perinatal anxiety has not been strong (Fairbrother et al 2019; Nath et al 2018). As such, the use of GAD-2 for public health screening is not yet clear, and a positive screen should be followed by assessment if clinically indicated.*